Type III secretion systems as targets for novel therapeutics.
IDrugs
; 12(10): 636-41, 2009 Oct.
Article
em En
| MEDLINE
| ID: mdl-19790014
ABSTRACT
Bacterial pathogens use common virulence factors to cause disease. One such virulence factor is the type III secretion system (T3SS), which allows for the direct injection of bacterial proteins, called effector proteins, into the contacting host cell. Pathogens with defective T3SSs are 1000- to 1 million-fold attenuated in animal models of infection. Thus, targeting antivirulence therapies to virulence factors such as the T3SS may provide a novel approach to treating infections. This article provides an overview of approaches used in identifying various classes of T3SS inhibitors, to enable the use of such inhibitors as novel therapeutics.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Drogas em Investigação
/
Sistemas de Liberação de Medicamentos
/
Proteínas de Escherichia coli
Tipo de estudo:
Prognostic_studies
Limite:
Animals
/
Humans
Idioma:
En
Revista:
IDrugs
Ano de publicação:
2009
Tipo de documento:
Article